These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 20669013)

  • 1. Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism.
    Shi HY; Yan J; Zhu WH; Yang GP; Tan ZR; Wu WH; Zhou G; Chen XP; Ouyang DS
    Eur J Clin Pharmacol; 2010 Nov; 66(11):1131-6. PubMed ID: 20669013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers.
    Wang G; Lei HP; Li Z; Tan ZR; Guo D; Fan L; Chen Y; Hu DL; Wang D; Zhou HH
    Eur J Clin Pharmacol; 2009 Mar; 65(3):281-5. PubMed ID: 18982321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers.
    Lei HP; Wang G; Wang LS; Ou-yang DS; Chen H; Li Q; Zhang W; Tan ZR; Fan L; He YJ; Zhou HH
    Ann Pharmacother; 2009 Apr; 43(4):726-31. PubMed ID: 19299322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
    Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
    Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.
    Scholz I; Oberwittler H; Riedel KD; Burhenne J; Weiss J; Haefeli WE; Mikus G
    Br J Clin Pharmacol; 2009 Dec; 68(6):906-15. PubMed ID: 20002085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.
    Kakuda TN; Van Solingen-Ristea R; Aharchi F; Smedt GD; Witek J; Nijs S; Vyncke V; Hoetelmans RM
    J Clin Pharmacol; 2013 Jan; 53(1):41-50. PubMed ID: 23400742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers.
    Jiang T; Rong Z; Xu Y; Chen B; Xie Y; Chen C; Lu Y; Shen Y; Li H; Sun J; Chen H
    Clin Drug Investig; 2013 Jan; 33(1):1-9. PubMed ID: 23179471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Voriconazole and fluconazole increase the exposure to oral diazepam.
    Saari TI; Laine K; Bertilsson L; Neuvonen PJ; Olkkola KT
    Eur J Clin Pharmacol; 2007 Oct; 63(10):941-9. PubMed ID: 17676319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of CYP2C19 phenotype with voriconazole plasma concentration in children.
    Narita A; Muramatsu H; Sakaguchi H; Doisaki S; Tanaka M; Hama A; Shimada A; Takahashi Y; Yoshida N; Matsumoto K; Kato K; Kudo K; Furukawa-Hibi Y; Yamada K; Kojima S
    J Pediatr Hematol Oncol; 2013 Jul; 35(5):e219-23. PubMed ID: 23588332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.
    Weiss J; Ten Hoevel MM; Burhenne J; Walter-Sack I; Hoffmann MM; Rengelshausen J; Haefeli WE; Mikus G
    J Clin Pharmacol; 2009 Feb; 49(2):196-204. PubMed ID: 19033450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes.
    Shimizu M; Uno T; Yasui-Furukori N; Sugawara K; Tateishi T
    Eur J Clin Pharmacol; 2006 Aug; 62(8):597-603. PubMed ID: 16783561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of CYP2C19, CYP2C9, CYP3A4, and FMO3 Genetic Polymorphisms and Sex on the Pharmacokinetics of Voriconazole after Single and Multiple Doses in Healthy Chinese Subjects.
    Liu S; Yao X; Tao J; Zhao S; Sun S; Wang S; Tian X
    J Clin Pharmacol; 2024 Aug; 64(8):1030-1043. PubMed ID: 38654529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring.
    Hassan A; Burhenne J; Riedel KD; Weiss J; Mikus G; Haefeli WE; Czock D
    Ther Drug Monit; 2011 Feb; 33(1):86-93. PubMed ID: 21192313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects.
    Yin OQ; Tomlinson B; Chow MS
    Clin Pharmacol Ther; 2005 Oct; 78(4):370-7. PubMed ID: 16198656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers.
    Lee S; Kim BH; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    J Clin Pharmacol; 2012 Feb; 52(2):195-203. PubMed ID: 21383338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles.
    Chung H; Lee H; Han HK; An H; Lim KS; Lee YJ; Cho JY; Yoon SH; Jang IJ; Yu KS
    Drug Des Devel Ther; 2015; 9():2609-16. PubMed ID: 25999694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers.
    Purkins L; Wood N; Ghahramani P; Kleinermans D; Layton G; Nichols D
    Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):30-6. PubMed ID: 14616411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical implication of therapeutic drug monitoring on voriconazole from the aspect of the analysis for CYP2C19 gene].
    Kimura M; Yamagishi Y; Kawasumi N; Hagihara M; Hasegawa T; Mikamo H
    Jpn J Antibiot; 2010 Jun; 63(3):255-64. PubMed ID: 20976881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers.
    Wang Y; Zhang H; Meng L; Wang M; Yuan H; Ou N; Zhang H; Li Z; Shi R
    Eur J Clin Pharmacol; 2010 Jun; 66(6):563-9. PubMed ID: 20414645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.
    Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
    Br J Clin Pharmacol; 2005 Jul; 60(1):61-8. PubMed ID: 15963095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.